BioIVT, a New York-based research partner and biospecimen solutions provider for drug and diagnostic development, acquired PrecisionMed a Carlsbad, CA-based supplier of human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics.
The amount of the deal was not disclosed.
Looking ahead, PrecisionMed will continue to operate out of its current headquarters and maintain its existing network of donor and collection sites.
Led by CEO Eric Leach, PrecisionMed is a supplier of human biological material for research, and it is the private global source of longitudinally collected human cerebrospinal fluid (CSF) from living normal controls and diseased populations. The regulatory-compliant and privacy-protected biorepository contains more than 170,000 samples of CSF, whole blood, serum, plasma, PBMCs, and urine collected under Institutional Review Board-approved clinical protocols. This collection of annotated biospecimens was amassed from PrecisionMed’s sizable network of donors and collection sites. Each biospecimen includes detailed clinical data, such as the donor’s diagnosis, demographics, family medical histories, treatment responses, and disease progression. Since 1996, its annotated human biological samples have been utilized by more than 600 pharmaceutical and biotechnology companies, and academic research organizations worldwide.
Led by CEO and PhD Richard Haigh, BioIVT enables smart science and accelerates medical research by delivering personalized biospecimen solutions and services to the life science and diagnostic industries. It specializes in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids.
FinSMEs
19/07/2023